Since the relation between GLP-1 agonists and pancreatic cancer is still unclear, the aim of this systematic review and meta-analysis is to assess if these anti-hyperglycaemic medications have an association with pancreatic cancer. The gene discussed is GLP1R; the disease is familial pancreatic carcinoma.